Christelle Johnson, MS, PhD

ACE ImmunoID Platform for reverse translation

Laboratory models have been central to the fast evolving field of immuno-oncology and immunotherapy drug development. We continue to learn from ...READ MORE
Erin Newburn, MS, PhD

Ethnic disparities in precision genomics

The premise of the right drug for the right patient at the right time is critical for indications from cardiovascular and infectious disease to the latest immuno-oncology strategies.  It’s imperative to comprehend which patient will derive benefit from ...READ MORE
Erin Newburn, MS, PhD

Refining neoantigen load

Tumor mutational burden (TMB) has now been established as a positive predictive biomarker of response to immune checkpoint inhibitors with more studies demonstrating correlations between the overall mutational landscape and clinical benefit ...READ MORE
Sean Michael Boyle, MS, PhD Erin Newburn, MS, PhD |

Overcoming the obstacles of neoantigen identification

Neoantigen-based cancer vaccines represent new, truly personalized therapeutic approaches to treating cancer.READ MORE
Erin Newburn, MS, PhD

Resistance to immunotherapy: The elusive routes of immune escape

Achieving a durable clinical response is the ultimate goal in immuno-oncology clinical trials. With immunotherapies showing long-lasting, unprecedented responses in cancer indications such as melanoma and Non-Small Cell Lung Cancer (NSCLC), these immune-boosting drugs seem to be displaying genuine advancesREAD MORE